| Active substance |
Peptide |
| Also known as |
Bremelanotide |
| Blood pressure |
May cause transient increases in blood pressure |
| Chemical name |
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Dosage (medical) |
1.75 mg subcutaneously |
| Dosage (sports) |
Not applicable |
| Effects |
Increases sexual arousal and spontaneous erections |
| Formula |
C50H68N14O10 |
| Half-life |
Approximately 2.7 hours |
| Hepatotoxicity |
No significant hepatotoxicity reported |
| Lab Test |
Specific tests for PT 141 are not typically part of standard drug screenings |
| Main action |
Melanocortin receptor agonist |
| Side effects |
Nausea, flushing, headache, hyperpigmentation, respiratory infections |
| Storage conditions |
Store at 2В°C to 8В°C (36В°F to 46В°F) |
| Substance class |
Peptide hormone |
| Trade name |
Vyleesi |
| Use in sports |
Not typically used in sports |
| Water Retention |
Minimal |
| Active ingredient, mg |
20 |
| Release form |
Cartridge |
| Manufacturer |
SunSci Pharmaceutical |
| Packing |
Packing (1 Cartridge) |
